Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N. Tanzawa S, et al. Among authors: ochiai r. Ther Adv Med Oncol. 2022 Jul 29;14:17588359221116603. doi: 10.1177/17588359221116603. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923924 Free PMC article.
Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review.
Ota S, Sakamoto T, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Sasajima Y, Mizota A, Seki N. Ota S, et al. Among authors: ochiai r. Case Rep Oncol. 2019 Jan 11;12(1):47-52. doi: 10.1159/000493850. eCollection 2019 Jan-Apr. Case Rep Oncol. 2019. PMID: 30792644 Free PMC article.
Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome following Its Appropriate Differential Diagnosis.
Ota S, Fujigaki Y, Tamura Y, Kojima K, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Seki N. Ota S, et al. Among authors: ochiai r. Case Rep Oncol. 2019 Jan 11;12(1):53-58. doi: 10.1159/000493851. eCollection 2019 Jan-Apr. Case Rep Oncol. 2019. PMID: 30792645 Free PMC article.
Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.
Seki N, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, Watanabe K. Seki N, et al. Among authors: ochiai r. Case Rep Oncol. 2019 Jan 21;12(1):84-90. doi: 10.1159/000493256. eCollection 2019 Jan-Apr. Case Rep Oncol. 2019. PMID: 30792647 Free PMC article.
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.
Seki N, Natsume M, Ochiai R, Haruyama T, Ishihara M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, Watanabe K. Seki N, et al. Among authors: ochiai r. Case Rep Oncol. 2019 Jan 21;12(1):91-97. doi: 10.1159/000493088. eCollection 2019 Jan-Apr. Case Rep Oncol. 2019. PMID: 30792648 Free PMC article.
Importance and Difficulty of Differentiating BMA-induced AFF Prodromal Symptoms from Hormonal Therapy-related Femoral Pain.
Ota S, Tokizaki T, Sugimoto M, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Kawano H, Seki N. Ota S, et al. Among authors: ochiai r. Intern Med. 2020 Mar 15;59(6):855-857. doi: 10.2169/internalmedicine.3157-19. Epub 2019 Nov 22. Intern Med. 2020. PMID: 31761883 Free PMC article.
Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Ishihara M, Ochiai R, Haruyama T, Sakamoto T, Tanzawa S, Honda T, Ota S, Ichikawa Y, Ishida T, Watanabe K, Seki N. Ishihara M, et al. Among authors: ochiai r. Transl Lung Cancer Res. 2021 Jan;10(1):221-232. doi: 10.21037/tlcr-20-777. Transl Lung Cancer Res. 2021. PMID: 33569306 Free PMC article.
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL).
Nogami N, Kubo T, Bessho A, Sakugawa M, Ikeo S, Yokoyama T, Seki N, Ochiai R, Fujimoto N, Murakami S, Kaira K, Harada T, Kishino D, Takiguchi Y, Shimokawa T, Kiura K, Yamashita N, Okamoto H. Nogami N, et al. Among authors: ochiai r. Jpn J Clin Oncol. 2024 Jul 7;54(7):805-812. doi: 10.1093/jjco/hyae044. Jpn J Clin Oncol. 2024. PMID: 38594880 Free PMC article. Clinical Trial.
261 results